BioCardia (BCDA)
(Delayed Data from NSDQ)
$2.49 USD
-0.21 (-7.78%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.49 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
BCDA 2.49 -0.21(-7.78%)
Will BCDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCDA
Bet on 5 Top-Ranked Stocks With Rising P/E
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
BCDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
Other News for BCDA
FDA Approves CardiAMP? Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
BioCardia price target adjusted to $25 from $4 at H.C. Wainwright
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
BCDA Stock Earnings: BioCardia Reported Results for Q2 2024
BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript